Given the widespread use of GLP-1 analogs for metabolic disorders, these findings suggest potential sex-dependent therapeutic effects during inflammatory conditions and highlight the importance of considering biological sex in evaluating GLP-1 analog responses. This evidence concerns the gene GCG and metabolic disease.